I am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Shares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company’s plans to cement its prime position in the burgeoning obesity drug market in the face of stiff competition from industry titans like Eli Lilly and an array of smaller biotech startups.
Amycretin is an oral medicine that targets the same GLP-1 hormone as other weight loss drugs like Novo’s Wegovy and Lilly’s Zepbound, as well as stimulating another hormone, amylin, which regulates hunger.Novo said amycretin appeared to be safe and well-tolerated and had a similar side effect profile to its other medicines in the field like semaglutide, the injectable GLP-1 drug sold as Ozempic for diabetes and Wegovy for weight loss.
While stressing that the trial was small, Novo’s head of development Martin Lange Holst said the promising results justify further research into the pill. He said Novo would move forward with the drug and begin a larger Phase 2 trial in the second half of this year, with results expected in early 2026.Novo is also testing a subcutaneous form of amycretin that, like Wegovy, would be delivered by regular injection. The early stage trial is ongoing and data could be released in 2025.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Obesity's Effect on Neonatal Outcomes Is Dose-DependentInfants born to mothers with higher classes of obesity are at increased risk for adverse outcomes like intraventricular hemorrhage and respiratory distress syndrome, new research shows.
Lire la suite »
Obesity Disrupts Mitochondria, And We May Have Figured Out HowThe Best in Science News and Amazing Breakthroughs
Lire la suite »
Over 1 Billion People Now Have Obesity, Study Finds: What To Know About Global Weight TrendsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Lire la suite »
More than 1 billion people worldwide are now estimated to have obesityA new analysis suggests that the prevalence of obesity has doubled in women, tripled in men and quadrupled in children and adolescents from 1990 to 2022.
Lire la suite »
Anti-Obesity Medication Stopped My Obsessive Thoughts About Food and Helped Me Become a Stronger WomanFor me, the mental benefits of taking an anti-obesity medication are just as important as the physical benefits
Lire la suite »
Obesity Affects More Than 1 Billion Around the WorldThe global obesity epidemic has grown to include children as well as adults.
Lire la suite »